Navidea Biopharmaceuticals Inc (NAVB) Sees Large Decline in Short Interest

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 402,082 shares, a decline of 95.1% from the April 15th total of 8,149,924 shares. Based on an average daily trading volume, of 41,896 shares, the short-interest ratio is currently 9.6 days. Currently, 5.3% of the shares of the stock are short sold.

NYSEAMERICAN NAVB opened at $1.43 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $1.21 and a 1-year high of $7.40.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter. The firm had revenue of $0.14 million for the quarter.

In other Navidea Biopharmaceuticals news, major shareholder John K. Jr. Scott purchased 357,143 shares of the company’s stock in a transaction dated Friday, March 22nd. The stock was bought at an average cost of $0.14 per share, for a total transaction of $50,000.02. Following the completion of the transaction, the insider now owns 22,261,565 shares in the company, valued at $3,116,619.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders bought 367,443 shares of company stock valued at $67,230.

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. BlackRock Inc. increased its holdings in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 0.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,498,050 shares of the biopharmaceutical company’s stock after buying an additional 6,975 shares during the period. BlackRock Inc. owned 24.89% of Navidea Biopharmaceuticals worth $345,000 as of its most recent filing with the Securities and Exchange Commission.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Featured Story: How mutual funds make money

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.